A grave neurodegenerative disease like Alzheimer’s whose cure is still unknown can now be managed with Dthera Sciences’ DTHR-ALZ, a novel digital therapy device which has been bestowed with the prestigious Breakthrough Device designation by the FDA.
Have you gone out and left the television on? Have you ever forgot to buy the item for which you went shopping for? These are examples of prospective memory failure, which could be an early sign of Alzheimer's disease.
The condition of memory loss is termed as Alzheimer’s disease, affecting more than 5 million people and there is still no definite cure. A research team reported that an experimental drug could treat Alzheimer’s disease by slowing down the process of clear thinking and memory.
A phase 2 study on BAN2401, a monoclonal antibody that hits soluble amyloid beta oligomers, showed that it limits cognitive decline in patients with slight cognitive injury or premature Alzheimer’s dementia on two scales and removed brain amyloid in 81% of patients in the trial.
Risk of Alzheimer's disease increases with reduction in levels of plasmalogens, a class of lipids produced by the liver that constitute cell membranes in the brain, confirms new research presented at the Alzheimer's Association International Conference (AAIC) 2018 by Mitchel A. Kling, MD, an associate professor of Psychiatry in the Perelman School of Medicine at the University of Pennsylvania and the Veterans Affairs Medical Center.
In a breakthrough finding, revealed through the final analysis of a mid-stage trial, Japanese pharmaceutical firm, Eisai Co and Biogen Inc’s drug for Alzheimer’s proved beneficial for patients who received the highest dose.
In a research study led by Yuksel Agca, associate professor of veterinary pathology and a researcher in the Comparative Medicine Program in the MU College of Veterinary Medicine, it was found that two proteins namely APP and PS1, were the key factors linked to Alzheimer’s disorder, by carrying out the research work in rat model. If the accumulation of amyloid-β could be manipulated, it could lead to a decrease in the onset of Alzheimer Disease.
EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
Washington University School of Medicine sleep specialist Yo-El Ju, MD, led a research team that found circadian rhythm disruptions occur in people whose memories are intact but whose brain scans show early, preclinical evidence of Alzheimer's disease. She previously had discovered that people with clinical symptoms of Alzheimer's have disturbances in their internal body clocks that affect the sleep/wake cycle. Credit: Washington University School of Medicine.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.